# Bausch & Lomb Corp: financial statements, quarterly

BLCO · NYSE · CIK 1860742 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/blco.md) · [Financials](/companies/blco/financials.md) · [Filings](/companies/blco/filings.md) · [Insiders](/companies/blco/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/blco/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,173 d](/filings/0001860742-26-000007.md) | [1,099](/filings/0001860742-25-000008.md) | [1,216](/filings/0001860742-25-000018.md) | [1,196](/filings/0001860742-25-000023.md) | [1,280 d](/filings/0001860742-26-000007.md) | [1,137](/filings/0001860742-26-000062.md) | [1,278](/filings/0001860742-26-000088.md) | [1,281](/filings/0001860742-26-000111.md) | [1,405 d](/filings/0001860742-26-000007.md) | [1,244](/filings/0001860742-26-000062.md) | [1,394](/filings/0001860742-26-000088.md) | [1,375](/filings/0001860742-26-000111.md) |
| Selling, general and administrative | $m | [483 d](/filings/0001860742-26-000007.md) | [504](/filings/0001860742-25-000008.md) | [535](/filings/0001860742-25-000018.md) | [511](/filings/0001860742-25-000023.md) | [532 d](/filings/0001860742-26-000007.md) | [563](/filings/0001860742-26-000062.md) | [579](/filings/0001860742-26-000088.md) | [528](/filings/0001860742-26-000111.md) | [564 d](/filings/0001860742-26-000007.md) | [544](/filings/0001860742-26-000062.md) | [588](/filings/0001860742-26-000088.md) | [556](/filings/0001860742-26-000111.md) |
| Operating income | $m | [49.0 d](/filings/0001860742-26-000007.md) | [6.0](/filings/0001860742-25-000008.md) | [26.0](/filings/0001860742-25-000018.md) | [43.0](/filings/0001860742-25-000023.md) | [87.0 d](/filings/0001860742-26-000007.md) | [(83.0)](/filings/0001860742-26-000062.md) | [(11.0)](/filings/0001860742-26-000088.md) | [95.0](/filings/0001860742-26-000111.md) | [112 d](/filings/0001860742-26-000007.md) | [33.0](/filings/0001860742-26-000062.md) | [83.0](/filings/0001860742-26-000088.md) | [155](/filings/0001860742-26-000111.md) |
| Income tax | $m | [(6.0) d](/filings/0001860742-26-000007.md) | [73.0](/filings/0001860742-25-000008.md) | [72.0](/filings/0001860742-25-000018.md) | [(66.0)](/filings/0001860742-25-000023.md) | [(8.0) d](/filings/0001860742-26-000007.md) | [31.0](/filings/0001860742-26-000062.md) | [(89.0)](/filings/0001860742-26-000088.md) | [22.0](/filings/0001860742-26-000111.md) | [71.0 d](/filings/0001860742-26-000007.md) | [6.0](/filings/0001860742-26-000062.md) | [(1.0)](/filings/0001860742-26-000088.md) | [23.0](/filings/0001860742-26-000111.md) |
| Net income | $m | [(54.0) d](/filings/0001860742-26-000007.md) | [(167)](/filings/0001860742-25-000008.md) | [(151)](/filings/0001860742-25-000018.md) | [4.0](/filings/0001860742-25-000023.md) | [(3.0) d](/filings/0001860742-26-000007.md) | [(212)](/filings/0001860742-26-000062.md) | [(62.0)](/filings/0001860742-26-000088.md) | [(28.0)](/filings/0001860742-26-000111.md) | [(58.0) d](/filings/0001860742-26-000007.md) | [(71.0)](/filings/0001860742-26-000062.md) | [(14.0)](/filings/0001860742-26-000088.md) | [32.0](/filings/0001860742-26-000111.md) |
| Diluted EPS | $ per share | not reported | [(0.48)](/filings/0001860742-25-000008.md) | [(0.43)](/filings/0001860742-25-000018.md) | [0.01](/filings/0001860742-25-000023.md) | not reported | [(0.60)](/filings/0001860742-26-000062.md) | [(0.18)](/filings/0001860742-26-000088.md) | [(0.08)](/filings/0001860742-26-000111.md) | not reported | [(0.20)](/filings/0001860742-26-000062.md) | [(0.04)](/filings/0001860742-26-000088.md) | [0.09](/filings/0001860742-26-000111.md) |
| Basic EPS | $ per share | not reported | [(0.48)](/filings/0001860742-25-000008.md) | [(0.43)](/filings/0001860742-25-000018.md) | [0.01](/filings/0001860742-25-000023.md) | not reported | [(0.60)](/filings/0001860742-26-000062.md) | [(0.18)](/filings/0001860742-26-000088.md) | [(0.08)](/filings/0001860742-26-000111.md) | not reported | [(0.20)](/filings/0001860742-26-000062.md) | [(0.04)](/filings/0001860742-26-000088.md) | [0.09](/filings/0001860742-26-000111.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.3](/filings/0001860742-25-000004.md) | [0.3](/filings/0001860742-24-000008.md) | [0.3](/filings/0001860742-24-000014.md) | [0.3](/filings/0001860742-24-000018.md) | [0.3](/filings/0001860742-26-000007.md) | [0.2](/filings/0001860742-25-000008.md) | [0.3](/filings/0001860742-25-000018.md) | [0.3](/filings/0001860742-25-000023.md) | [0.4](/filings/0001860742-26-000111.md) | [0.3](/filings/0001860742-26-000062.md) | [0.4](/filings/0001860742-26-000088.md) | [0.5](/filings/0001860742-26-000111.md) |
| Current assets | $bn | [2.7](/filings/0001860742-25-000004.md) | [2.7](/filings/0001860742-24-000008.md) | [2.8](/filings/0001860742-24-000014.md) | [2.8](/filings/0001860742-24-000018.md) | [2.8](/filings/0001860742-26-000007.md) | [2.7](/filings/0001860742-25-000008.md) | [2.8](/filings/0001860742-25-000018.md) | [2.9](/filings/0001860742-25-000023.md) | [3.0](/filings/0001860742-26-000111.md) | [2.8](/filings/0001860742-26-000062.md) | [2.9](/filings/0001860742-26-000088.md) | [3.1](/filings/0001860742-26-000111.md) |
| Total assets | $bn | [13.4](/filings/0001860742-25-000004.md) | [13.3](/filings/0001860742-24-000008.md) | [13.3](/filings/0001860742-24-000014.md) | [13.5](/filings/0001860742-24-000018.md) | [13.5](/filings/0001860742-26-000007.md) | [13.4](/filings/0001860742-25-000008.md) | [13.8](/filings/0001860742-25-000018.md) | [13.8](/filings/0001860742-25-000023.md) | [14.0](/filings/0001860742-26-000111.md) | [13.8](/filings/0001860742-26-000062.md) | [13.9](/filings/0001860742-26-000088.md) | [14.0](/filings/0001860742-26-000111.md) |
| Current liabilities | $bn | [1.6](/filings/0001860742-25-000004.md) | [1.6](/filings/0001860742-24-000008.md) | [1.7](/filings/0001860742-24-000014.md) | [1.8](/filings/0001860742-24-000018.md) | [1.7](/filings/0001860742-26-000007.md) | [1.7](/filings/0001860742-25-000008.md) | [1.8](/filings/0001860742-25-000018.md) | [1.9](/filings/0001860742-25-000023.md) | [1.9](/filings/0001860742-26-000111.md) | [1.8](/filings/0001860742-26-000062.md) | [1.9](/filings/0001860742-26-000088.md) | [2.0](/filings/0001860742-26-000111.md) |
| Total liabilities | $bn | [6.5](/filings/0001860742-25-000004.md) | [6.6](/filings/0001860742-24-000008.md) | [6.7](/filings/0001860742-24-000014.md) | [6.9](/filings/0001860742-24-000018.md) | [6.9](/filings/0001860742-26-000007.md) | [7.0](/filings/0001860742-25-000008.md) | [7.3](/filings/0001860742-25-000018.md) | [7.3](/filings/0001860742-25-000023.md) | [7.5](/filings/0001860742-26-000111.md) | [7.3](/filings/0001860742-26-000062.md) | [7.4](/filings/0001860742-26-000088.md) | [7.4](/filings/0001860742-26-000111.md) |
| Long-term debt | $bn | [4.5](/filings/0001860742-25-000004.md) | [4.6](/filings/0001860742-24-000008.md) | [4.6](/filings/0001860742-24-000014.md) | [4.6](/filings/0001860742-24-000018.md) | [4.7](/filings/0001860742-26-000007.md) | [4.8](/filings/0001860742-25-000008.md) | [4.9](/filings/0001860742-25-000018.md) | [4.9](/filings/0001860742-25-000023.md) | [5.0](/filings/0001860742-26-000111.md) | [5.0](/filings/0001860742-26-000062.md) | [5.0](/filings/0001860742-26-000088.md) | [5.0](/filings/0001860742-26-000111.md) |
| Current portion of debt | $bn | [0.0](/filings/0001860742-25-000004.md) | [0.0](/filings/0001860742-24-000008.md) | [0.0](/filings/0001860742-24-000014.md) | [0.0](/filings/0001860742-24-000018.md) | [0.0](/filings/0001860742-26-000007.md) | [0.0](/filings/0001860742-25-000008.md) | [0.0](/filings/0001860742-25-000018.md) | [0.0](/filings/0001860742-25-000023.md) | [0.0](/filings/0001860742-26-000111.md) | [0.0](/filings/0001860742-26-000062.md) | [0.0](/filings/0001860742-26-000088.md) | [0.0](/filings/0001860742-26-000111.md) |
| Shareholders' equity | $bn | [6.9](/filings/0001860742-25-000004.md) | [6.7](/filings/0001860742-24-000008.md) | [6.5](/filings/0001860742-24-000014.md) | [6.6](/filings/0001860742-24-000018.md) | [6.5](/filings/0001860742-26-000007.md) | [6.4](/filings/0001860742-25-000008.md) | [6.4](/filings/0001860742-25-000018.md) | [6.4](/filings/0001860742-25-000023.md) | [6.4](/filings/0001860742-26-000111.md) | [6.4](/filings/0001860742-26-000062.md) | [6.4](/filings/0001860742-26-000088.md) | [6.4](/filings/0001860742-26-000111.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [15.0 d](/filings/0001860742-26-000007.md) | [41.0](/filings/0001860742-25-000008.md) | [15.0 d](/filings/0001860742-25-000018.md) | [154 d](/filings/0001860742-25-000023.md) | [22.0 d](/filings/0001860742-26-000007.md) | [(25.0)](/filings/0001860742-26-000062.md) | [35.0 d](/filings/0001860742-26-000088.md) | [137 d](/filings/0001860742-26-000111.md) | [136 d](/filings/0001860742-26-000007.md) | [32.0](/filings/0001860742-26-000062.md) | [153 d](/filings/0001860742-26-000088.md) | [233 d](/filings/0001860742-26-000111.md) |
| Capital expenditure | $m | [84.0 d](/filings/0001860742-26-000007.md) | [67.0](/filings/0001860742-25-000008.md) | [72.0 d](/filings/0001860742-25-000018.md) | [60.0 d](/filings/0001860742-25-000023.md) | [92.0 d](/filings/0001860742-26-000007.md) | [110](/filings/0001860742-26-000062.md) | [89.0 d](/filings/0001860742-26-000088.md) | [74.0 d](/filings/0001860742-26-000111.md) | [76.0 d](/filings/0001860742-26-000007.md) | [100](/filings/0001860742-26-000062.md) | [71.0 d](/filings/0001860742-26-000088.md) | [55.0 d](/filings/0001860742-26-000111.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [350](/filings/0001860742-24-000008.md) | [351](/filings/0001860742-24-000014.md) | [351](/filings/0001860742-24-000018.md) | [351](/filings/0001860742-25-000008.md) | [352](/filings/0001860742-25-000018.md) | [354](/filings/0001860742-25-000023.md) | [353](/filings/0001860742-26-000062.md) | [354](/filings/0001860742-26-000088.md) | [354](/filings/0001860742-26-000111.md) | [355](/filings/0001860742-26-000062.md) | [357](/filings/0001860742-26-000088.md) | [362](/filings/0001860742-26-000111.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 357,497,374 at 2026-10-21, from the cover of the [10-Q filed 2026-10-28](/filings/0001860742-26-000111.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 18:28 ET. No prices; not investment advice.